Monk, Bradley J <br/><br/>
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.  [electronic resource] 

 -  Gynecologic oncology  Mar 2013 
 - 573-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2012.11.038  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Carboplatin--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Maintenance Chemotherapy<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Placebos<br/>Quality of Life<br/>Treatment Outcome